Does CVS Caremark cover Zepbound and Foundayo?
The short answer
CVS Caremark covers Zepbound only if your plan sponsor elects to cover GLP-1 weight-management medicines. It added Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026, and said that from June 1, 2026 it would remove the new-to-market block on Foundayo where plans approve it. Sponsors can still customize their own coverage.
Key takeaways
- Caremark's Zepbound return applies only to plan sponsors that elect to cover GLP-1 weight-management medicines.
- Your plan sponsor, usually your employer, decides whether these medicines are covered, and can customize coverage.
- Removing the block on Foundayo doesn't add it to every plan. Your plan sponsor has to approve it.
- Call the number on your prescription card. Ask if the drug is on your formulary, its tier, and whether prior authorization applies.
What the published policies say
CVS Caremark: Foundayo pbm-standard-formulary varies by plan
CVS Caremark announced that from June 1, 2026 it no longer blocks Foundayo as a new-to-market drug. Whether it is covered depends on the plan sponsor approving it for coverage.
Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.
CVS Caremark: Zepbound pbm-standard-formulary preferred
CVS Caremark announced that Zepbound returns to its most common commercial template formularies as an additional preferred option on October 1, 2026, after having been removed. This applies to plan sponsors that choose to cover GLP-1 weight-management drugs, and sponsors can still customize their own coverage.
CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members.
Policies differ between plans from the same insurer and change during the year. Your own plan documents decide.
CVS Caremark is a pharmacy benefit manager, not an insurer. It runs the prescription side of many employer and health plans and publishes template formularies (lists of covered drugs) that those plans can adopt or change. So the record we hold for Caremark is different from the insurer policies on our other pages. It’s a company announcement about formulary status, and it contains no clinical criteria.
What the announcement says about Zepbound
In CVS Caremark’s words: “CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members.”
Three things follow from that sentence.
First, the date. Zepbound had been removed from Caremark’s most common commercial template formularies. Its return took effect on October 1, 2026.
Second, the word “additional.” Zepbound comes back as an additional preferred option, alongside what was already preferred. The announcement doesn’t describe it as replacing anything.
Third, the condition. The change is for plan sponsors that choose to cover GLP-1 weight-management drugs, and sponsors can still customize their own coverage. A template formulary listing doesn’t put the drug on a plan that excludes weight-loss medicines.
What it says about Foundayo
The announcement also covers Foundayo, an oral medicine. Effective June 1, 2026, CVS Caremark said it would remove the new-to-market block on Foundayo, which it describes as “a new oral GLP-1 therapy, where approved for coverage by plans.”
A new-to-market block is a hold a benefit manager places on a recently launched drug. Lifting the block doesn’t add Foundayo to every plan. Our record marks its status as varying by plan, because coverage still depends on your plan sponsor approving it.
What to do if Caremark manages your benefit
- Find out who your plan sponsor is. For most people, it’s an employer. The sponsor decides whether weight-management GLP-1s are covered at all.
- Call Caremark on the number on your prescription card. Ask whether Zepbound or Foundayo is on your plan’s formulary now, what tier it’s on, and whether prior authorization (the plan’s approval before it pays) applies.
- If you were moved off Zepbound when it was removed and want to go back to it, talk to your prescriber. Our switching planner shows what the labels say, and it doesn’t convert doses between medicines.
- If you need a prior authorization, the checklist of common criteria shows what other insurers ask for, which is a reasonable guide to what to gather.
- If you’re refused, read how to appeal a denial and draft the request with the appeal letter generator.
If your plan covers Zepbound, the Lilly savings card can lower a covered fill of the single-dose pen to as little as $25, and a covered Foundayo fill to as little as $25, within the card’s limits. If your sponsor hasn’t elected coverage, the Zepbound and Foundayo guides list the self-pay prices, and the insurance overview explains the other routes.
Frequently asked questions
Is Zepbound covered by CVS Caremark again?
CVS Caremark said it would add Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026, after having removed it. That applies to plan sponsors who elect to cover GLP-1 weight-management medicines. Sponsors can customize their own coverage, so confirm with your plan before you assume it applies to you.
Does CVS Caremark cover Foundayo?
It depends on your plan. CVS Caremark announced that effective June 1, 2026 it would remove the new-to-market block on Foundayo, where approved for coverage by plans. Removing the block makes coverage possible. Whether Foundayo is covered for you depends on your plan sponsor approving it.
Does CVS Caremark require prior authorization for Zepbound?
The announcement we hold doesn't set out prior authorization criteria. It only describes formulary status. Ask Caremark or your plan whether a prior authorization applies, and ask for the written criteria. Many of the insurer policies in our records do require one for weight-loss GLP-1 medicines.
My insurance card says Caremark. Who decides whether my GLP-1 is covered?
Your plan sponsor, which is usually your employer or health plan. CVS Caremark manages the drug benefit and publishes template formularies. But its announcement says the change serves plan sponsors who elect to provide coverage of GLP-1 weight-management medicines. The benefit decision sits with the sponsor.
Sources (4)
- 1.CVS Caremark: CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options
“Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.”
- 2.CVS Caremark: CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options
“CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members.”
- 3.
- 4.
Related pages
- What insurance covers Wegovy, Zepbound and other GLP-1 medicines?
- Wegovy and Zepbound prior authorization: a criteria checklist
- How to appeal a Wegovy or Zepbound insurance denial
- What is Zepbound? Uses, cost, doses and side effects
- Foundayo (orforglipron): the once-daily weight loss pill
- Appeal letter generator
